Pradaxa
Pradaxa, Xarelto and apixaban vie for attention
September 6, 2010Research and Development, Sales and Marketing Pradaxa, Xarelto, apixaban, atrial fibrilation
New data has intensified the competition between three rival would-be cardiology blockbusters. Boehringer Ingelheim’s Pradaxa (dabigatran) and Bayer’s Xarelto (rivaroxaban) …
Novel anticoagulants set to lead atrial fibrillation market
July 9, 2010Sales and Marketing Brinavess, Multaq, Pradaxa, Xarelto, apixaban, atrial fibrilation
Novel anticoagulants set to capture the atrial fibrillation market by 2019, according to a new report. Analysts Decision Resources say …
New anti-clotting drugs: stopping the silent killers
June 28, 2010Research and Development, Sales and Marketing Pradaxa, VTE, Xarelto, atrial fibrilation, thrombosis
Blood clots are a major killer, but the threat they pose is poorly understood by the general public compared to …
Ogilvy wins Pradaxa account
June 3, 2010Medical Communications Boehringer, Ogilvy, Pradaxa
Boehringer Ingelheim has awarded OgilvyHealthPR the global communications brief for its oral blood-thinner Pradaxa. The agency was appointed after a …
Patients ignorant of blood clot risks
April 14, 2010Sales and Marketing Pradaxa, VTE, thrombosis
Many patients are not aware that they are at risk from blood clots when staying in hospital, according to new …
Study boost for atrial fibrillation drugs
March 17, 2010Research and Development Pradaxa, VTE, Xarelto, apixaban, betrixaban
Two rival drugs have both shown benefits over warfarin in patients with atrial fibrillation, according to new research. Boehringer Ingelheim’s …
Pradaxa data boosts Boehringer
September 1, 2009Research and Development, Sales and Marketing Boehringer, Pradaxa
Boehringer Ingelheim has unveiled new positive data for its blood-thinner Pradaxa, showing it reduces the risk of stroke compared to …
Pradaxa approved by NICE
September 26, 2008Sales and Marketing NICE, Pradaxa, clot, cv
NICE has recommended Boehringer Ingelheim's novel anti-clotting pill Pradaxa, giving it a marketing edge over Bayer's rival treatment Xarelto. Pradaxa …
Latest content
